Penumbra Q3 revenue rises 26.8% to $270.9 million; net income $9.2 million
Penumbra reported third-quarter 2023 results, with revenue up 26.8% from a year earlier and GAAP net income of $9.2 million, compared with a net loss of $2.3 million in the third quarter of 2022. The company also said it expects fourth-quarter revenue growth of 28% to 31% and cited full-year 2023 revenue guidance of $1.05 billion to $1.07 billion.
Key points
- Q3 2023 revenue was $270.9 million, up 26.8% (25.9% in constant currency) from $213.7 million in Q3 2022.
- GAAP income from operations was $12.6 million, including a one-time $18.2 million acquired in-process R&D expense; non-GAAP income from operations was $33.2 million.
- Thrombectomy product revenue rose 38.0% to $179.1 million, a company record.
- Full-year 2023 revenue guidance is $1.05 billion to $1.07 billion, with fourth-quarter growth expected at 28% to 31%.
The filing
Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 1:12 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 02, 2023.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.